Skinvisible (SKVI) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.12 Bn | 626.36 Bn | 17.26 Bn |
| 2 | AbbVie | 440.93 Bn | 434.36 Bn | 12.70 Bn |
| 3 | Merck | 364.34 Bn | 357.20 Bn | 12.21 Bn |
| 4 | Novartis Ag | 268.31 Bn | 260.62 Bn | 11.24 Bn |
| 5 | Pfizer | 158.49 Bn | 146.79 Bn | 10.94 Bn |
| 6 | Sanofi | 52.52 Bn | 45.14 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.27 Bn | 44.27 Bn | - |
| 8 | Incyte | 25.01 Bn | 20.47 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.18 Bn | 18.51 Bn | 683.80 Mn |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.99% |
| Mar 31, 2026 | 9.31% |
| Dec 31, 2025 | 2.62% |
| Sep 30, 2025 | 9.39% |
| Jun 30, 2025 | 2.26% |
| Mar 31, 2025 | 8.16% |
| Dec 31, 2024 | 2.97% |
| Sep 30, 2024 | 7.91% |
| Jun 30, 2024 | 11.91% |
| Mar 31, 2024 | 3.56% |
| Dec 31, 2023 | 3.84% |
| Sep 30, 2023 | 20.64% |
| Jun 30, 2023 | 6.71% |
| Mar 31, 2023 | -27.21% |
| Dec 31, 2022 | -13.63% |
| Sep 30, 2022 | 5.40% |
| Jun 30, 2022 | 21.15% |
| Mar 31, 2022 | 5.09% |
| Dec 31, 2021 | 2.74% |
| Sep 30, 2021 | 15.92% |